Can Eli Lilly Keep The Margin You Are Now Paying For?

Can Eli Lilly Keep The Margin You Are Now Paying For?

Mon, August 24, 2026 at 5:39 PM GMT+3 3 min read

• LLY -1.44%

The share of every sales dollar Eli Lilly keeps as operating profit has roughly doubled against its own long-run record, and it is volume rather than price holding it there.

Eli Lilly (LLY) now keeps close to half of every sales dollar as operating profit. A holder who has watched these shares run owns that margin as much as the medicines, because a roughly doubled margin only stays in the price if it lasts. So is this a level the business can hold, or the top of the incretin cycle?

Two Medicines And A Cost Base That Did Not Follow

In the quarter ended June 2026, operating margin was 49.7%, against a 25.8% history. Price moved the other way: U.S. price fell 3%, and 9% excluding a change to rebate and discount estimates, which management does not expect to repeat in the second half of 2026. What rose was volume. Total revenue grew 48% year over year while marketing, selling and administrative costs grew 25%, and Mounjaro and Zepbound alone combined for $14.9 billion of revenue and $6.3 billion of the growth over Q2 2025.

The volume arrived through an operating cost base that did not have to grow with it, and that gap is where the June quarter's margin came from. Operating margin, revenue growth and gross margin, all three running above their own history, make the June 2026 quarter the most unusual joint configuration in 14 years of the company's own record, which is what separates a structural break from a good quarter.

Management Has Already Raised Its Own Outlook

Full-year 2026 revenue is now guided to $85 billion to $87 billion, and the non-GAAP performance margin guide, management's own measure and not the operating margin above, moved up two percentage points at both ends, to 49% to 50.5%. That range sits below the 54.8% the same measure reached in the June quarter. Growth of that kind, arriving alongside a raised margin guide, is the property the Trefis High Quality Portfolio looks for in its holdings.

The Company Is Trading Price For Volume On Purpose

The Medicare GLP-1 Bridge program, live since the start of July 2026, widened coverage for Eli Lilly's obesity medicines to 35% more people in the United States than before. Management expects U.S. price to fall further once broader CVS access begins in Q4 2026, and describes the medical exception process some patients have used as a short-term route. Management says the decline is already embedded in the guide and that volume growth will more than offset it. If that offset fails, 49.7% was a peak rather than a level.

The Line To Watch Is Price

The shares have already traveled: up 78% over the past twelve months, 59 percentage points ahead of the market, and about 2% below their 52-week high. The business changed underneath that run, and whether the run happened for this reason is a separate question. Because this margin expansion is primarily driven by operating leverage rather than pricing power, its sustainability largely depends on whether volume growth continues to outpace net price erosion in upcoming quarters. U.S. price excluding the rebate and discount adjustments, down 9% in the June quarter. Until then, each further raise to the full-year margin range, management's non-GAAP performance margin guide, is the running evidence either way.

Managing Single-Stock Concentration Risk in Your Portfolio

Most portfolios hold a position that has quietly grown larger than anyone planned. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.